Use TAP2 (Therapeutic Antibody Profiling) Online
Commercially Available TAP2 (Therapeutic Antibody Profiling) No-Code Web Server
Try TAP2 (Therapeutic Antibody Profiler)
TAP2: The Therapeutic Antibody Profiler for In Silico Developability Design
TAP2 (Therapeutic Antibody Profiler) is a groundbreaking computational tool designed to identify developability risks in therapeutic antibodies long before they enter the wet lab. Developed by the Oxford Protein Informatics Group (OPIG), TAP serves as the industry’s first "Lipinski’s Rule of Five" for biologics. By comparing candidate antibody models against a reference set of successful clinical-stage therapeutics (CSTs), TAP flags anomalies in surface properties that could lead to poor stability, high levels of aggregation, or high viscosity.
Key Innovations: Clinically-Contextualized Intelligence
TAP moves beyond simple sequence analysis by building 3D homology models to evaluate surface-exposed biophysical characteristics.
Five Core Developability Guidelines: Evaluates candidates across five critical metrics calibrated against clinical-stage therapeutic distributions:
Total CDR Length: Captures binding-site shape and potential paratope complexity.
Patches of Surface Hydrophobicity (PSH): Identifies clusters of exposed hydrophobic residues likely to drive aggregation.
Patches of Positive Charge (PPC): Detects regions of dense positive charge linked to poor expression and high clearance.
Patches of Negative Charge (PNC): Highlights dense negative charge patches associated with chemical instability.
Structural Fv Charge Symmetry Parameter (SFvCSP): Measures asymmetry in net surface charges between heavy and light chains to predict viscosity risks.
Homology-Driven Modeling: Uses ABodyBuilder to generate high-fidelity structural representations of variable domain sequences.
Traffic-Light Flagging System: Assigns Amber flags for candidates in the extreme 5% of CST distributions and Red flags for values previously unobserved in clinical therapeutics.
Sequence Liability Identification: Automatically reports potential manufacturing liabilities such as lysine glycation, aspartate isomerization, and asparagine deamidation sites.
Performance Benchmarks: Validation Against Clinical Success
TAP guidelines are highly conserved across therapeutic-like antibodies, with a proven track record of identifying unrectifiable developability issues.
Metric | CST Median Value | Amber Flag Region (CST) | Red Flag Region (CST) |
Total CDR Length | 48 residues | 54–60 residues | > 60 residues |
CDR Vicinity PSH | 123.30 | 156.20 – 173.85 | > 173.85 |
CDR Vicinity PPC | < 1.0 | 1.25 – 3.16 | > 3.16 |
CDR Vicinity PNC | < 1.0 | 1.84 – 3.50 | > 3.50 |
SFvCSP | 3.34 | -20.40 to -6.30 | < -20.40 |
Scientific Breakthroughs in Biotherapeutic Engineering
Predicting Aggregation and Viscosity
High levels of hydrophobicity in the highly exposed CDR regions have been repeatedly implicated in aggregation and polyspecificity. TAP’s PSH metric successfully identifies these risks; for instance, the matured antibody MEDI-1912 was red-flagged for prohibitive aggregation levels before it reached the clinic.
Optimizing Expression via Charge Distribution
Dense negative charge patches can destabilize loop backbones and crash expression levels. TAP’s PNC metric correctly red-flagged the matured AB001 candidate, which showed expression levels seven times lower than its lead precursor. Back-mutation of these residues to neutral asparagine returned the candidate to the acceptable clinical range.
Contextualizing Natural Human Repertoires
TAP metrics were validated by comparing CST distributions against snapshots of healthy human antibody gene repertoires. This analysis suggests that while CSTs share many features with human antibodies, not every natural human antibody is a suitable therapeutic candidate, underscoring the need for specialized therapeutic profiling.
TAP on Tamarind Bio: Professional Antibody Profiling
Tamarind Bio provides a managed environment to execute TAP’s structural modeling and surface analysis pipelines in seconds without local infrastructure requirements.
No-Code Web Dashboard: Input heavy- and light-chain variable domain sequences and receive a comprehensive developability report in under 30 seconds.
Interactive 3D Visualization: Explore your antibody's surface properties and potential sequence liabilities through an integrated molecular viewer.
How to Use TAP on Tamarind Bio
Access the Platform: Log in to tamarind.bio and select the Therapeutic Antibody Profiler (TAP) tool.
Input Sequences: Enter the amino acid sequences of your antibody’s heavy- and light-chain variable domains.
Run Structural Analysis: The platform uses ABodyBuilder to generate a 3D homology model of your candidate.
Evaluate Developability Flags: Review the "traffic-light" status (Green, Amber, Red) for all five metrics against clinical benchmarks.
Inspect Sequence Liabilities: Identify specific motifs prone to post-translational modifications (e.g., lysine glycation or aspartate isomerization).
Export & Validate: Download the high-resolution homology model and developability report to prioritize your best leads for wet-lab validation.